Shares of Emcure Pharmaceuticals Ltd. experienced a significant surge, climbing 10 percent to reach a record high of Rs 2,180.80 in Wednesday's trading session. This impressive performance followed the pharmaceutical company's release of its September quarter (Q2 FY27) earnings, which largely met or exceeded analyst expectations.
Several leading brokerages have reiterated a positive outlook on Emcure Pharma shares, highlighting the company's consistent growth across both its domestic and international business segments.
Elara Securities Analysis and Outlook
Elara Securities noted that Emcure's Q2 FY27 performance was broadly in line with its projections, with revenue exceeding estimates by 6 percent, and EBITDA aligning as expected. While profit after tax (PAT) was slightly below expectations due to lower other income and a higher tax rate, the underlying operational strength was evident.
Key highlights from Elara's assessment include:
- Organic growth in Emcure's domestic business improved to 11 percent year-on-year (YoY).
- The international business demonstrated robust expansion, with Canada and Europe registering growth of 15 percent and 25 percent, respectively, in constant currency terms.
- The Rest-of-the-World (RoW) business segment grew an impressive 41 percent YoY.
- International revenue increased 34.5 percent YoY during the quarter.
Responding to this strong performance, Emcure's management raised its FY27 growth guidance to approximately 20 percent, up from a previous mid-teens outlook. The company also expects to achieve the upper end of its guidance for 70-100 basis points in margin expansion. Consequently, Elara Securities has increased its FY27-FY29 estimated core earnings per share (EPS) by 5-9 percent and raised its target price to Rs 2,158, maintaining an 'Accumulate' rating on the stock.
HDFC Securities Recommends 'Buy'
HDFC Securities has issued a 'Buy' rating for Emcure Pharma, setting a target price of Rs 2,208 with a time horizon extending up to the next Diwali. The brokerage suggested a buying range of Rs 1,863-1,898, with an additional buying level of Rs 1,681 on dips.
HDFC Securities anticipates strong growth across all business segments and expects operating leverage to drive a compound annual growth rate (CAGR) of 18.5 percent in EBITDA and 25 percent in PAT over the FY26-FY29 period.
Growth Strategy and Supporting Factors
Emcure's domestic growth strategy, as highlighted by HDFC Securities, focuses on:
- Enhanced execution across priority franchises.
- Improved field force productivity.
- Expansion of its product pipeline through internal development and strategic partnerships.
Factors supporting HDFC Securities' positive view include market share gains by key brands, a robust product pipeline in international markets, and new launches combined with improved field force productivity driving domestic formulation (DF) growth.
Potential Risks
Despite the optimistic outlook, HDFC Securities also flagged potential risks that could impact Emcure's growth trajectory. These include regulatory inspection-related issues, adverse pricing regulations from the National Pharmaceutical Pricing Authority (NPPA), delays in product approvals or launches, and unexpected competition in niche product categories.